This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. D ...
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep31: Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
MP3•Episode home
Manage episode 421615490 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
- FDA Approves High-Concentration Cyltezo
- Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars
- DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
- Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD
- New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching
- Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
- Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
- Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
- Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
156 episodes
MP3•Episode home
Manage episode 421615490 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
- FDA Approves High-Concentration Cyltezo
- Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars
- DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
- Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD
- New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching
- Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
- Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
- Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
- Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
156 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.